ADC (Antibody Drug Conjugates) Contract Manufacturing Market, 2030 –

ADC (Antibody Drug Conjugates) Contract Manufacturing Market, 2030 –

ADC (Antibody Drug Conjugates) Contract Manufacturing Market, 2030 –

DUBLIN–(BUSINESS WIRE)–The “ADC Contract Manufacturing Market (4th Edition) by Phase of Development, Type of Component Manufacturing, Target Indications, Type of Payload Used, Type of Linker, Type of Antibody Origin, Type of Antibody Isotype and Geography, 2020-2030” report has been added to’s offering.

The report offers a comprehensive study of the current scenario and future potential of the ADC contract manufacturing market. The study features an in-depth analysis, highlighting the capabilities of contract services providers engaged in this domain.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the ADC contract manufacturing market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030.

Report Highlights

  • An overview of the current market with respect to the players involved in the contract manufacturing of ADCs. It features information on company size, year of establishment, types of services offered (antibody manufacturing/HPAPI or cytotoxic payload manufacturing/linker manufacturing/conjugation/fill-finish), location of headquarters, location of manufacturing facilities, scale of operations (preclinical, clinical and commercial), and additional development services (proof-of-concept studies/process development and scale-up/analytical development). In addition, the chapter includes details on the antibody contract manufacturers and HPAPI/cytotoxic payload contract manufacturers.
  • Elaborate profiles of contract manufacturers that offer conjugation services at the commercial scale. Each profile provides a brief overview of the company, its financial information, details on ADC manufacturing capabilities, location of facilities, recent developments, and a comprehensive future outlook.
  • A competitiveness analysis of contract manufacturers across key geographical areas, featuring a four-dimensional bubble representation, taking into consideration supplier strength (company size and its experience in this field), service strength (number of ADC services offered, number of additional services offered and location of ADC manufacturing facilities), manufacturing strength (scale of operation and number of ADC manufacturing facilities) and company size (small-sized, mid-sized and large).
  • A detailed analysis of the expansions undertaken (since 2012) by various service providers for augmenting their respective ADC service portfolios, based on a number of parameters, including year of expansion, type of expansion (capacity expansion and new facility), type of service offered (manufacturing services, analytical/development services and fill/finish), geographical location of facility, scale of operation (preclinical, clinical and commercial) and most active players (in terms of number of instances).
  • An analysis of the recent partnerships (since 2012) focused on manufacturing of ADCs, based on various parameters, such as year of agreement, type of agreement (manufacturing agreement, research agreement, product development, licensing agreement, service alliance, acquisition and others), key players and the geographical distribution of this activity.
  • A qualitative analysis highlighting the various factors that need to be taken into consideration by ADC developers, while deciding whether to manufacture their respective products in-house or outsource the manufacturing to a contract service provider.

Key Questions Answered

  • Who are the leading ADC contract manufacturers, across the world?
  • In which regions are majority of the ADC manufacturing facilities located?
  • What percentage of ADC manufacturing operations are outsourced?
  • What are the key regions targeted by contract manufacturers for expansions or new facility set-up?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • What factors are likely to decide if ADC manufacturing should be done in-house or outsourced?
  • What is the overall cost distribution across various steps of ADC manufacturing process?
  • What is overall ADC manufacturing/bioconjugation capacity (in grams/batch) of contract manufacturers?
  • How many ADCs are under development and approved?
  • Which geographies are most active in conducting ADC clinical trials?
  • What is the current, global demand for ADC products?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. ADC Contract Manufacturing Service Providers: Market Landscape

5. Company Profiles

6. Company Competitiveness Analysis

7. ADC Contract Manufacturing Service Providers: Recent Expansions

8. ADC Contract Manufacturing Service Providers: Partnerships And Collaborations

9. Make Versus Buy Decision Making

10. Value Chain Analysis

11. ADC Manufacturing: Capacity Analysis

12. ADC Therapeutics: Market Overview

13. Novel ADC Conjugation Technology Platforms

14. Geographical Clinical Trials Analysis

15. ADC Therapeutics: Demand Analysis

16. Regional Capability Assessment Analysis

17. Market Sizing And Opportunity Analysis

18. SWOT Analysis

19. Impact Of Covid-19 Pandemic On The ADC Contract Manufacturing Market

20. Concluding Remarks

21. Interview Transcripts

22. Appendix 1: Tabulated Data

For more information about this report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900